Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: January 25, 2017
Reporting Period: Fourth quarter and full year 2016
This filing announces the results of operations for the fourth quarter and full year 2016. Detailed financial data is contained in the news release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced Exhibit 99.1 (Press Release).
The company utilizes non-GAAP financial measures to assess performance, specifically "net earnings from continuing operations excluding specified items."
Material Changes and Unusual Items
The filing details specific adjustments made to non-GAAP measures to exclude unusual or unpredictable factors. These adjustments include:
- Expenses associated with acquisitions, including bridge facility fees and other debt-related costs.
- Charges related to cost reduction initiatives and other expenses.
- Adjustments to tax expense resulting from the resolution of various tax positions from prior years.
- Foreign exchange loss related to Venezuela.
- Expenses related to an adjustment of Abbott's equity investment in Mylan N.V.
- A gain on the sale of a portion of Abbott's position in Mylan stock.
- A decrease in the fair value of contingent consideration related to a business acquisition.
- Recognition of deferred taxes associated with the pending disposition of AMO.
- Exclusion of intangible amortization expense.
Guidance, Outlook, and Management Commentary
Management states that these non-GAAP measures provide useful information for evaluating ongoing business performance and are used internally to monitor business performance. However, the company cautions investors to consider these measures in addition to, and not as a substitute for, GAAP financial measures.
The filing text does not contain specific forward-looking guidance, outlook figures, or detailed risk factors beyond the mention of the pending disposition of AMO and the Venezuela foreign exchange loss.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP revenue, earnings, and cash flow figures.
- Verify the reconciliation between GAAP and non-GAAP net earnings to understand the magnitude of the excluded items.
- Assess the impact of the pending disposition of AMO on future deferred tax recognition.
- Monitor the status of the Mylan N.V. equity investment and related gains/losses.
- Evaluate the ongoing impact of foreign exchange volatility, specifically regarding Venezuela.